Skip to content

A multicenter randomized double-blind placebo-controlled clinical study of Xiaoke Yin in the treatment of impaired glucose tolerance

A multicenter randomized double-blind placebo-controlled clinical study of Xiaoke Yin in the treatment of impaired glucose tolerance

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000114
Enrollment
Unknown
Registered
2025-01-15
Start date
2024-12-01
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired glucose tolerance

Interventions

Control group:Lifestyle intervention and Placebo
treatment group:Lifestyle intervention and Xiaoke Yin

Sponsors

Eye Hospital China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) meet the diagnostic standards of Western medicine; (2) Aged 18-70 years; (3) Body mass index of 21-32kg/m2; (4) Sign informed consent and participate in this study voluntarily.

Exclusion criteria

Exclusion criteria: (1) Have previously or currently been diagnosed with type 2 diabetes; (2) Pregnant or lactating women; (3) Use drugs that may affect blood sugar or are receiving hypoglycemic drugs and other treatments; (4) Other endocrine diseases that may lead to IGT or abnormal blood glucose; (5) Combined with serious heart and lung diseases or liver insufficiency renal insufficiency and other serious diseases; (6) Cognitive dysfunction inability to communicate or inadequacy to participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
OGTT recovery rate;

Secondary

MeasureTime frame
HOMA-ß;2hPG;Lipids four;HbA1c;HOMA-IR;TCM physique scale;

Countries

China

Contacts

Public ContactLu Jing

Eye Hospital China Academy of Chinese Medical Sciences

jinglu00@sina.cn13611351223

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026